Transcriptome-wide RNA modification profiling via Adduct-IP
Transcriptome-wide RNA modification profiling via Adduct-IP
批准号:
8773425
负责人:
BRADLEY R. CAIRNS
金额:
$22.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-15 至 2016-05-31
关键词:
5 fluorouridineAzacitidineBiologicalBiological ProcessBrainCancer cell lineCatalogingCatalogsCell LineCellsClinicalComplementComplementary DNAComplexCytosineDataDefectDetectionDevelopmentDiseaseDyskeratosis CongenitaEnzymesEventFoundationsFunctional RNAGene Expression ProfileGenesGeneticGenomeGrowthHela CellsHereditary DiseaseHumanImmunoprecipitationInfertilityLinkMalignant NeoplasmsMental RetardationMessenger RNAMethylationMethyltransferaseModificationNucleotidesPathogenesisPathway interactionsPositioning AttributePost-Transcriptional RNA ProcessingPrecipitationProcessPropertyProteinsPseudouridineRNARibosomal RNARoleSiteSmall Nuclear RibonucleoproteinsStressStructureSyndromeSystemTechniquesTechnologyTestingTransfer RNAUridineValidationVariantadductbasebisulfitecancer cellembryonic stem cellgain of functionhuman embryonic stem cellimprovedin vivoinnovationmembermethylomenovelnovel strategiesnucleotide analogpublic health relevanceresearch studyresponsestable cell linetooltumorigenesis
中文摘要
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant):
Post-transcriptional RNA modifications can impact the sequence, structure and function of RNA molecules. Over 100 distinct modified nucleotides have been characterized so far in RNA, and RNA modifying enzymes comprise a marked proportion of genomes. However, for certain key modifications their full scope, specific enzymes and biological roles are not well understood - due in part to lack of appropriate transcriptome-wide technologies. This is despite the profound clinical implications observed upon loss/gain of function of many RNA modification enzymes, which can confer diverse genetic syndromes, mental retardation, and infertility. We recently developed Aza-IP, a mechanism-based novel technique that greatly enriches the precise direct targets of RNA cytosine methyltransferases (m5C-RMTs). We tested Aza-IP in HeLa cells, and conducted transcriptome-wide target profiling of two important human m5C-RMTs; DNMT2 and NSUN2. Here, in Aim 1 we apply Aza-IP for target profiling of all eight other m5C-RMTs in both HeLa cells and hESCs. In Aim 2, we expand the applicability of the mechanism-based enrichment strategy - which can be generally referred to as 'Adduct-IP' - for target profiling of another important class of RNA modifying enzymes; pseudouridine synthases. Our mechanism-based 'Adduct-IP' approaches involve the in-vivo covalent attachment of the enzyme to its substrate. For Aza-IP, 5-azacytidine is transcriptionally incorporated in place of cytosine within all RNAs, leading to covalent attachment of the proper m5C-RMT at its specific target - which is followed by immuno-precipitation, release and cDNA sequencing. Aza-IP specifically enriches the direct targets of m5C- RMTs, and also generates a clear and penetrant C>G transversion 'signature' exclusively at the exact target cytosine. Importantly Aza-IP captures low copy RNA targets and also rare methylation events, which are under the detection limit of other techniques such as RNA bisulfite sequencing. Here, we aim to expand this technique to discover the targets for the remaining eight known human m5C-RMTs. Beyond m5C-RMTs, pseudouridine synthases are another important class of RNA modifying enzymes that isomerize specific uridines in various RNA species into pseudouridine. Pseudouridine is the most abundant modified nucleotide in RNA and is essential for proper structure and function of rRNAs, tRNAs and snRNAs. Although presence of pseudouridine in other RNA species (ncRNAs and mRNAs) is expected, the field is hampered by lack of tools for transcriptome-wide profiling of this modification which would reveal the scope of this modification. Interestingly, pseudouridine synthases can become irreversibly inhibited (through covalent linkage) by the nucleotide analogue 5-flurourdine through a similar mechanism as of 5-aza-C inhibition of m5C-RMTs. Here we aim to apply the Adduct-IP strategy for transcriptome-wide target profiling of selected pseudouridine synthases (such as DKC1), with significant involvement in a genetic disease (dyskeratosis congenita) and also in cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
-
批准号:10090925
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2020
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
-
批准号:10265515
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2020
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
-
批准号:10432077
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2020
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis
-
批准号:10646506
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2020
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
-
批准号:10406300
-
项目类别:
-
资助金额:$41.71万
-
财政年份:2019
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
-
批准号:10624437
-
项目类别:
-
资助金额:$37.36万
-
财政年份:2019
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
-
批准号:10005439
-
项目类别:
-
资助金额:$39.78万
-
财政年份:2019
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
-
批准号:10187618
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2019
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Identifying Epigenetic, Chromatin, and Transcriptomic landscapes to Improve SCNT Development in an Animal Model
-
批准号:9795100
-
项目类别:
-
资助金额:$43.69万
-
财政年份:2019
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
Epigenetic Mechanisms Driving Synovial Sarcomagenesis
-
批准号:10090570
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2017
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
FASEB SRC on Transcriptional Regulation During Cell Growth, Differentiation & Dev
-
批准号:7909307
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2010
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
A Center for Zebrafish Chromatin and Epigenetics
-
批准号:7864165
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2008
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
A Center for Zebrafish Chromatin and Epigenetics
-
批准号:8304257
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2008
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
A Center for Zebrafish Chromatin and Epigenetics
-
批准号:7498788
-
项目类别:
-
资助金额:$31.98万
-
财政年份:2008
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
A Center for Zebrafish Chromatin and Epigenetics
-
批准号:7692866
-
项目类别:
-
资助金额:$31.98万
-
财政年份:2008
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
A Center for Zebrafish Chromatin and Epigenetics
-
批准号:8080933
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2008
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
ANALYSIS OF THE CHROMATIN-REMODELING COMPLEX RSC
-
批准号:7653853
-
项目类别:
-
资助金额:$29.05万
-
财政年份:1999
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
ANALYSIS OF THE CHROMATIN-REMODELING COMPLEX RSC
-
批准号:7272836
-
项目类别:
-
资助金额:$24.67万
-
财政年份:1999
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
ANALYSIS OF THE CHROMATIN-REMODELING COMPLEX RSC
-
批准号:6032512
-
项目类别:
-
资助金额:$30.85万
-
财政年份:1999
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
ANALYSIS OF THE CHROMATIN-REMODELING COMPLEX RSC
-
批准号:6825358
-
项目类别:
-
资助金额:$26.01万
-
财政年份:1999
-
负责人:BRADLEY R. CAIRNS
-
依托单位:
国内基金
海外基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究
-
批准号:82100198
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:胡甜园
-
依托单位: